Alaric DeArment
Reporter

Latest From Alaric DeArment
Could Start-Up Adagio’s COVID-19 Antibody Have A Fighting Chance?
The company announced a $336m series C round, six months after it raised an $80m series B, to support development of an easily administered treatment ADG20.
#ClinicalTrialsSoWhite: How Drug Makers Are Using COVID-19 To Improve Trial Diversity
Efforts to improve trial diversity predate COVID-19, but the pandemic’s disproportionate effects on minority communities have brought the issue to the forefront.
A Hundred Drugs Contend: Chinese Biopharma Gains US Foothold
Legend/J&J’s CAR-T cilta-cel and Chi-Med’s surufatinib would follow BeiGene’s Brukinsa, which won FDA approval in November 2019.
Merck’s COVID-19 Therapeutic Development Path Gets A Little Harder
After backing off of MRK-7110 for hospitalized patients the company’s focus is on the oral antiviral molnupiravir for outpatients – which would be a huge win, but the drug has yet to fully prove itself in the clinic.
Do R&D Spending And Approvals Really Measure Innovation?
A lot of new drugs aren’t really all that innovative, which complicates the view that lower profitability will mean less biopharma innovation.
Sanofi Stays Bullish On Synthorx IL-2 Drug, But It’s Early Days
In an interview, oncology development exec Peter Adamson reiterated the company’s view that THOR-707 is best-in-class, but more data are needed to see where its efficacy stands amid the IL-2 herd.